Jürgen Schanzer

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

Wolfgang Schaefer, Jörg T. Regula, Monika Bähner et al. · Proceedings of the National Academy of Sciences · 2011 · 457 citations · Full text

Immunocytochemical Technique, Immunology, Immunodominance +26

Design, Synthesis, and Characterization of a Series of Cytochrome P₄₅₀3A-Activated Prodrugs (HepDirect Prodrugs) Useful for Targeting Phosph(on)ate-Based Drugs to the Liver^§

Mark D. Erion, K. Raja Reddy, Serge H. Boyer et al. · Journal of the American Chemical Society · 2004 · 157 citations

Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains

Jürgen Schanzer, Andreas Jekle, Jun‐ichi Nezu et al. · Antimicrobial Agents and Chemotherapy · 2011 · 62 citations · Full text

Immunology, Molecular Biology, Antiviral Drug +18

TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations

Raffaella Castoldi, Jürgen Schanzer, Christian Panke et al. · Protein Engineering Design and Selection · 2016 · 27 citations · Full text

Oncogenic Agent, Receptor Tyrosine Kinase, Immunology +14

Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2

Werner Scheuer, Markus Thomas, P Hanke et al. · mAbs · 2016 · 22 citations · Full text